The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
Abstract
Clinical studies using mitoxantrone, an anthraquinone, were begun in the United States in 1979. Subsequent phase II and III trials have shown that mitoxantrone has significant clinical activity in patients with breast cancer, acute leukemia, and lymphoma. The drug has antiviral, antibacterial, antiprotozoal, immunomodulating, and antineoplastic properties and is mutagenic in some animal systems. Its mechanism of action seems to involve both DNA intercalation and nonintercalative electrostatic interactions. The dose-limiting toxicity is myelosuppression when the drug is given on a single-dose, every-3-week schedule and mucositis when it is given daily for 5 days. Other toxicities include gastrointestinal and cardiac effects, the gastrointestinal toxicity being less severe and less frequent than that with the anthracycline anticancer drugs. Because of its low incidence of serious toxicities and effectiveness in treating certain solid tumors and leukemias, mitoxantrone is a promising new agent in the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 558
Anthracycline Antibiotic Augmentation of Microsomal Electron Transport and Free Radical Formation
BACHUR, N. R., GORDON, S. L., & GEE, M. V. (1977) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12453-x · Cited by 373
Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation
Mimnaugh, E. G., Trush, M. A., & Gram, T. E. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90417-2 · Cited by 163
Chemotherapy of non-small-cell lung cancer.
Ds, A., Young, L., Mason, N., & Salmon, S. E. (1985) · PubMed · Cited by 147
Molecular and biochemical pharmacology of mitoxantrone
Durr, F. E., Wallace, R. E., & Citarella, R. V. (1983) · Cancer Treatment Reviews · doi:10.1016/0305-7372(83)90016-6 · Cited by 131
Chemotherapy of advanced prostatic cancer Evaluation of response parameters
Schmidt, J. D., Johnson, D. E., Scott, W. W., Gibbons, R. P., Prout, G. R., & Murphy, G. P. (1976) · Urology · doi:10.1016/0090-4295(76)90085-6 · Cited by 130
Extravasation: A Hazard of Intravenous Therapy
MacCara, M. E. (1983) · Annals of Pharmacotherapy · doi:10.1177/106002808301701002 · Cited by 102
Pharmacology of mitoxantrone: mode of action and pharmacokinetics
Alberts, D. S., Peng, Y. M., Bowden, G. T., Dalton, W. S., & Mackel, C. (1985) · Investigational New Drugs · doi:10.1007/bf00174156 · Cited by 85
Disposition of mitoxantrone in cancer patients.
Alberts, D. S., Peng, Y. M., Leigh, S. A., Davis, T. P., & Woodward, D. L. (1985) · PubMed · Cited by 82
Cited by
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Hepatotoxicity of Chemotherapy
King, P. D., & Perry, M. C. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2-162 · Cited by 454
Cardiotoxicity of Cancer Therapy
Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.789 · Cited by 372
Hollingshead, L. M., & Faulds, D. (1991) · Drugs · doi:10.2165/00003495-199142040-00010 · Cited by 345
Metadata
- Authors
- SHENKENBERG, T. D., & VON HOFF, D. D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1986-07-01
- Volume
- 105
- Issue
- 1
- Pages
- 67-81
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2127264662
- Cited by
- 305
- References
- 13
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity. https://app.cochat.ai/papers/10.7326/0003-4819-105-1-67
- The paper
- SHENKENBERG, T. D., & VON HOFF, D. D. (1986). Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-105-1-67
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.